ADA and rheumatoid arthritis: Across RA trials (24, 26, 27, 29, 42, 43), upadacitinib demonstrated a protective effect on joint structure compared to placebo (evaluated by △mTSS ≤ 0, RR = 1.14, 95% CI [1.11, 1.18]), although this effect was similar to that of ADA, with a P-value of 0.72.